Download Full eBooks in PDF
Progress In Neurotherapeutics And Neuropsychopharmacology Volume 3 2008 Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Progress In Neurotherapeutics And Neuropsychopharmacology Volume 3 2008 book. This book definitely worth reading, it is an incredibly well-written.
Author : Jeffrey L. Cummings
Publisher : Cambridge University Press
Page : 185 pages
File Size : 55,5 Mb
Release : 2012-07-26
Category : Medical
ISBN : 9781107405875
An essential update of clinical trials in the management of neurological and neuropsychiatric disorders.
Author : Jeffrey L. Cummings
Publisher : Cambridge University Press
Page : 314 pages
File Size : 44,7 Mb
Release : 2008-03-06
Category : Medical
ISBN : 9780521862554
An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders.
Author : Jeffrey L. Cummings
Publisher : Cambridge University Press
Page : 298 pages
File Size : 47,8 Mb
Release : 2007-04-12
Category : Medical
ISBN : 052186254X
An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders.
Author : Jeffrey L. Cummings
Publisher : Cambridge University Press
Page : 0 pages
File Size : 45,5 Mb
Release : 2012-07-26
Category : Psychology
ISBN : 1107405807
Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.
Author : Peter Healey,Steve Rayner
Publisher : Earthscan
Page : 287 pages
File Size : 46,9 Mb
Release : 2012
Category : Medical
ISBN : 9781849773669
First Published in 2008. Routledge is an imprint of Taylor & Francis, an informa company.
Author : Anonim
Publisher : Unknown
Page : 796 pages
File Size : 48,7 Mb
Release : 2006
Category : Catalogs, Union
ISBN : STANFORD:36105111058843
Author : S. Nassir Ghaemi
Publisher : CRC Press
Page : 363 pages
File Size : 46,7 Mb
Release : 2002-05-06
Category : Medical
ISBN : 9780203909027
This practical reference examines the advantages and disadvantages of polypharmacy in psychiatry, and provides up-to-date clinical guidelines on the appropriate use of combinations of pharmacological therapy in major psychiatric disorders-including multidisciplinary approaches to treatment, such as social work and psychopharmacology, and an examina
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse
Publisher : National Academies Press
Page : 483 pages
File Size : 44,7 Mb
Release : 2017-09-28
Category : Medical
ISBN : 9780309459570
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author : Allan Tasman,Jerald Kay,Jeffrey A. Lieberman,Michael B. First,Michelle Riba
Publisher : John Wiley & Sons
Page : 2765 pages
File Size : 42,8 Mb
Release : 2015-03-30
Category : Medical
ISBN : 9781118845479
Now in a new Fourth Edition, Psychiatry remains the leading reference on all aspects of the current practice and latest developments in psychiatry. From an international team of recognised expert editors and contributors, Psychiatry provides a truly comprehensive overview of the entire field of psychiatry in 132 chapters across two volumes. It includes two new sections, on psychosomatic medicine and collaborative care, and on emergency psychiatry, and compares Diagnostic and Statistical Manual (DSM-5) and International Classification of Diseases (ICD10) classifications for every psychiatric disorder. Psychiatry, Fourth Edition is an essential reference for psychiatrists in clinical practice and clinical research, residents in training, and for all those involved in the treatment psychiatric disorders. Includes a a companion website at www.tasmanpsychiatry.com featuring PDFs of each chapter and downloadable images
Author : Anonim
Publisher : Academic Press
Page : 404 pages
File Size : 41,7 Mb
Release : 2020-06-29
Category : Medical
ISBN : 9780128201909
The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Population Health and Public Health Practice,Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda
Publisher : National Academies Press
Page : 487 pages
File Size : 50,7 Mb
Release : 2017-03-31
Category : Science
ISBN : 9780309453073
Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis. These landmark changes in policy have impacted cannabis use patterns and perceived levels of risk. However, despite this changing landscape, evidence regarding the short- and long-term health effects of cannabis use remains elusive. While a myriad of studies have examined cannabis use in all its various forms, often these research conclusions are not appropriately synthesized, translated for, or communicated to policy makers, health care providers, state health officials, or other stakeholders who have been charged with influencing and enacting policies, procedures, and laws related to cannabis use. Unlike other controlled substances such as alcohol or tobacco, no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively. Shifting public sentiment, conflicting and impeded scientific research, and legislative battles have fueled the debate about what, if any, harms or benefits can be attributed to the use of cannabis or its derivatives, and this lack of aggregated knowledge has broad public health implications. The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. This report provides a research agendaâ€"outlining gaps in current knowledge and opportunities for providing additional insight into these issuesâ€"that summarizes and prioritizes pressing research needs.
Author : Aysegul Yildiz,Pedro Ruiz,Charles Nemeroff
Publisher : Oxford University Press
Page : 720 pages
File Size : 49,6 Mb
Release : 2015-05-22
Category : Medical
ISBN : 9780199300556
As a major mainstay of clinical focus and research today, bipolar disorder affects millions of individuals across the globe with its extreme and erratic shifts of mood, thinking and behavior. Edited by a team of experts in the field, The Bipolar Book: History, Neurobiology, and Treatment is a testament and guide to diagnosing and treating this exceedingly complex, highly prevalent disease. Featuring 45 chapters from an expert team of contributors from around the world, The Bipolar Book delves deep into the origins of the disorder and how it informs clinical practice today by focusing on such topics as bipolar disorder occurring in special populations, stigmatization of the disease, the role genetics play, postmortem studies, psychotherapy, treatments and more. Designed to be the definitive reference volume for clinicians, students and researchers, Ayseg?l Yildiz, Pedro Ruiz and Charles Nemeroff present The Bipolar Book as a "must have" for those caregivers who routinely deal with this devastating disease.
Author : British Medical Association
Publisher : CRC Press
Page : 164 pages
File Size : 41,8 Mb
Release : 1997-11-18
Category : Medical
ISBN : 9057023180
At the last Annual Representative Meeting of the British Medical Association a motion was passed that `certain additional cannabinoids should be legalized for wider medicinal use.'' This report supports this landmark statement by reviewing the scientific evidence for the therapeutic use of cannabinoids and sets the agenda for change. It will be welcomed by those who believe that cannabinoids can be used in medical treatment. The report discusses in a clear and readable form the use and adverse effects of the drug for nausea, multiple sclerosis, pain, epilepsy, glaucoma, and asthma.
Author : National Research Council,Division on Behavioral and Social Sciences and Education,Board on Behavioral, Cognitive, and Sensory Sciences,Division on Engineering and Physical Sciences,Standing Committee for Technology Insight--Gauge, Evaluate, and Review,Committee on Military and Intelligence Methodology for Emergent Neurophysiological and Cognitive/Neural Science Research in the Next Two Decades
Publisher : National Academies Press
Page : 215 pages
File Size : 44,5 Mb
Release : 2008-12-06
Category : Medical
ISBN : 9780309118941
Emerging Cognitive Neuroscience and Related Technologies, from the National Research Council, identifies and explores several specific research areas that have implications for U.S. national security, and should therefore be monitored consistently by the intelligence community. These areas include: neurophysiological advances in detecting and measuring indicators of psychological states and intentions of individuals the development of drugs or technologies that can alter human physical or cognitive abilities advances in real-time brain imaging breakthroughs in high-performance computing and neuronal modeling that could allow researchers to develop systems which mimic functions of the human brain, particularly the ability to organize disparate forms of data. As these fields continue to grow, it will be imperative that the intelligence community be able to identify scientific advances relevant to national security when they occur. To do so will require adequate funding, intelligence analysts with advanced training in science and technology, and increased collaboration with the scientific community, particularly academia. A key tool for the intelligence community, this book will also be a useful resource for the health industry, the military, and others with a vested interest in technologies such as brain imaging and cognitive or physical enhancers.
Author : Zoran Rankovic,Richard Hargreaves,Matilda Bingham
Publisher : Royal Society of Chemistry
Page : 678 pages
File Size : 43,7 Mb
Release : 2012-10-08
Category : Science
ISBN : 9781849734943
The discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst the current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research and drug discovery. The editors will combine their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery and medicinal chemistry for major psychiatric disorders, such as schizophrenia, depression, anxiety, ADHD, bipolar disorder, addiction and autism.
